insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

KTTA · Pasithea Therapeutics Corp. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · KTTA

1Y3YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$2.94M-$1.36M$2.15M$1.73M-$1.58M$2.36M$1.75M-
SG&A$1.93M-$1.75M$1.66M$2.29M-$1.42M$1.80M$2.29M-
Total Operating Expenses----------
D&A--$5.0K$4.0K$4.2K---$4.7K-
Operating Income($4.88M)-($3.11M)($3.81M)($3.68M)-($3.00M)($3.95M)($4.04M)-
Interest Expense----------
Income Tax----------
Net Income($2.87M)-($3.04M)($3.72M)($3.56M)-($3.00M)($3.87M)($3.86M)-
EPS - Basic($0.12)-($0.41)($0.66)($3.70)-----
EPS - Diluted($0.12)-($2.87)($0.66)($3.70)-----

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$50.40M$55.16M$4.12M$7.22M$5.34M$6.92M$9.36M$7.97M$12.01M$16.33M
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$52.73M$56.46M$5.53M$8.64M$6.12M$7.37M$9.78M$8.64M$13.19M$16.69M
Total Assets$56.35M$60.24M$13.63M$17.01M$14.66M$16.06M$18.64M$17.66M$22.41M$26.12M
Current Liabilities$1.49M$4.97M$1.38M$1.74M$1.59M$1.12M$660.4K$1.39M$2.47M$2.63M
Long-term Debt----------
Total Liabilities$1.54M$5.02M$1.42M$1.83M$1.68M$1.28M$824.0K$1.49M$2.52M$2.72M
Stockholders' Equity$54.81M$55.22M$12.21M$23.40M$12.98M$14.78M$17.81M$16.18M$19.88M$23.40M
Retained Earnings($72.88M)($70.01M)($59.90M)($56.86M)($53.15M)($49.58M)($46.41M)($43.05M)($39.18M)($35.32M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($4.79M)---($4.32M)---($4.32M)-
Investing Cash Flow----------
Financing Cash Flow$750---$1.47M---$264.1K-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-5.1%--22.3%-21.8%-24.3%--16.1%-21.9%-17.2%-
Return on equity-5.2%--24.9%-15.9%-27.5%--16.8%-23.9%-19.4%-
Return on invested capital----------
Liquidity
Current ratio35.4011.354.024.973.846.5814.816.205.356.34
Quick ratio35.4011.354.024.973.846.5814.816.205.356.34
Cash ratio33.8411.092.994.153.356.1814.185.714.876.20
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.031.091.120.731.131.091.051.091.131.12
Liabilities / Assets0.030.080.100.110.110.080.040.080.110.10
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B0.3x-0.4x0.2x0.2x-0.3x0.3x0.4x-
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-32.5%--3.5%3.4%8.9%-20.7%-3.0%-25.8%-
Net income growth (YoY)19.5%--1.3%3.9%7.7%-17.0%-2.7%-9.1%-
EPS growth (YoY)96.8%---------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)322.3%273.5%-31.5%44.7%-34.7%-36.8%-37.2%-54.6%-49.2%-44.9%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Pasithea Therapeutics Corp. against the 5 most active filers in the same SIC group.